Interestingly, however, analysis of TCGA data suggests that IL-6 and IL-6R expression in the sarcoma TME may favorably impact OS, though we are unable to differentiate soluble IL-6R on our analysis, which may result in these somewhat paradoxical effects While our study does not answer these critical questions regarding which immune genes and signatures reliably predict prognosis and response to therapy, it does lends support to the validity of using the canine model for more detailed immune dissection. The gene discussed is IL6; the disease is sarcoma.